01.08.2005 16:12:00

King Pharmaceuticals Announces Date for Release of Second-Quarter 2005 Financial Results and Conference Call

BRISTOL, Tenn., Aug. 1 /PRNewswire-FirstCall/ -- King Pharmaceuticals, Inc. reported today that the Company plans to announce financial results for the second quarter ending June 30, 2005, prior to the market open on Tuesday, August 9, 2005. The Company also plans to provide a live conference call to discuss its financial results beginning at 1:00 p.m. E.D.T. later that same day. Conference call information will be provided when available via a subsequent press release.

King, headquartered in Bristol, Tennessee, is a vertically integrated pharmaceutical company that develops, manufactures, markets, and sells branded prescription pharmaceutical products. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.

This release contains forward-looking statements that reflect management's current views of future events and operations, including, but not limited to, statements pertaining to the anticipated date for release of the Company's financial results for the second quarter ending June 30, 2005 and subsequent conference call. These forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially from the forward-looking statements. An important factor that may cause results to differ is whether King is able to release the Company's financial results for second quarter ending June 30, 2005 and conduct its conference call as currently planned on August 9, 2005. King does not undertake to publicly update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Analysen zu Pfizer Inc.mehr Analysen

19.12.24 Pfizer Neutral UBS AG
17.12.24 Pfizer Buy Jefferies & Company Inc.
17.12.24 Pfizer Neutral UBS AG
17.12.24 Pfizer Neutral JP Morgan Chase & Co.
12.12.24 Pfizer Neutral JP Morgan Chase & Co.
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Pfizer Inc. 24,81 -1,84% Pfizer Inc.

Indizes in diesem Artikel

S&P 500 6 116,29 -0,04%